Background: The purpose of this study is to investigate the effects of administration order when a sedative drug (midazolam) and an opioid analgesic drug (fentanyl) is applied for moderate intravenous (IV) sedation in dentistry. Methods: A retrospective chart review was conducted in one dental clinic during its transition from a midazolam-first to a fentanyl-first protocol for dental procedures requiring moderate IV sedation. Physiological parameters, drug administration times, patient recovery times, drug dosages, and patient recall and satisfaction were investigated for differences. Results: A total of 76 charts (40 midazolam-first and 36 fentanyl-first administrations), were used in the analysis. Administering midazolam first resulted in an average 4.38 min (52%) decrease in administration times (P < 0.001), and a decrease in procedural recollection immediately following the procedure (P = 0.03), and 24 to 48 hours later (P = 0.009). Administering fentanyl first required an average of 2.43 mg (29%) less midazolam (P < 0.001). No significant differences were found for change in vital signs, minimum oxygen saturation levels, recovery times, and patient satisfaction (P > 0.05). Oxygen saturation levels did not drop below 90% for either group; however, 5 cases in the fentanyl-first group fell to between 90% and 92%, compared with 0 cases in the midazolam-first group. Conclusions: The administration order of fentanyl and midazolam may have different effects on patients and the sedation procedure. Findings from this study should be used to facilitate discussion among dental practitioners and to guide additional research investigating this topic.
INTRODUCTION
Moderate (conscious) sedation is a common pharmacological approach to managing psychological anxiety and physical pain associated with dental procedures including surgery. While maintaining patient responsiveness to verbal and tactile stimuli [1] , safety of conducting moderate sedation in dental clinic is well documented with infrequent complications [1, 2] . Preferred drug choices for administering moderate intravenous (IV) sedation are midazolam (benzodiazepine sedative) and fentanyl (opioid analgesic) because their safety and efficacy have been well established [3] [4] [5] [6] [7] [8] .
Other drug options for moderate IV sedation exist, but are beyond the scope of this article.
The Alberta Dental Association and College regulates and provides provincial practice standards for use of moderate sedation in dentistry [9] . Regulations provide strict rules for the environment, support personnel, and monitoring of airway patency, vitals, and oxyhemoglobin saturation (SpO 2 ). However, the administration order of the sedative/opioid two-drug moderate sedation is not prescribed. In most of North America, the administration order-whether the sedative or the opioid should be administered first-is determined at the discretion of the dentist based on clinician preference and/or assessment of the patient's individual need [3, 10] . For example, if a patient suffers from moderate to high anxiety and reduced anxiety, or recall of the procedure is the patients' expectation, a sedative-first approach may be preferred.
Whereas if pain is the patient's main concern, then opioid-first administration may be the better option [10] .
Teaching practices across North America prepare trainees to administer midazolam first, followed by fentanyl. As such, the administration order of midazolam first is likely guided by educational practice.
While logical arguments for prescription based on patient need exists, there is limited research or compelling evidence regarding how to prescribe sedative/analgesic administration order in dental sedation. One randomized control trial found no significant effects of fentanyl and midazolam order administration on patient pain, changes in vital signs, or satisfaction [3] . However, this study held drug dosages constant, whereas in general practice, drugs are typically titrated to effect (i.e., patient comfortable and appropriately responsive), with dosages varying depending on patient characteristics (e.g., anxiety) and procedural stimuli (e.g., complexity of the dental procedure). There is evidence, however, that opioid-first administration yields a substantial reduction in the amount of sedative needed to achieve similar degrees of moderate sedation due to a pharmacodynamic interaction [6, 11, 12] . A pharmacodynamic interaction occurs when the use of a combination of drugs results in a change in the clinical effect from that which would occur if either drug was used on its own. One study specifically demonstrated a 36% reduction in the amount of midazolam needed to titrate to a suitable end-point for oral surgery when the patient was pretreated with 0.1 mg/70 kg of fentanyl [6] . With the potential in reducing sedative dosage, jurisdictions, such as the United Kingdom, specify opioid-first administration for use in dental procedures [13] . Opioids are known to exert less profound effects on cardiovascular stability compared with sedatives [11] . More research is needed to determine whether the opioid-first technique is appropriate for administration of moderate IV sedation in dentistry.
Aware of the potential pharmacological benefits of opioid-first techniques, a dental clinic in Alberta, Canada, began to adopt a protocol for fentanyl-first administration.
Clinical observations when fentanyl was used first included an apparent decrease in discomfort with injection of the local anesthetic (i.e., patients exhibited less response, such as wincing, during needle insertions). This finding was attributed to the fact that by administering the opioid sooner, it reached peak effect before the procedure started. Eventually, this clinic decided to formally switch their protocol from midazolam first to fentanyl first. During the transition period from midazolam-first to fentanyl-first administrations, several dental procedures were performed. The purpose of the present study was to contribute to the evidence base of outcomes for sedative/opioid administration order in moderate IV sedation for dental procedures in a dental clinic environment, where charts and sedation records from this transition period were collected for analysis. Specifically, our study was designed to determine order effects on: patient safety and physiological parameters 
Sedation Procedures
Standards from the Alberta Dental Association and College are followed for all procedures [9] . Three personnel are present at each treatment: the dentist (IV sedation permit holder), a certified dental assistant, and Based on the safe sedation practice guideline for selecting the order of drug administration [14] , the change in order of the sedation from midazolam first to fentanyl first does not alter the aims or endpoints of moderate sedation or its measurement. The principle of titrating drug/drugs to optimal effect is critical to safely achieving a recognized sedation end-point, thereby avoiding inadvertent under-or over-sedation [15] . The use of fixed doses or boluses is unacceptable.
Fentanyl-first protocol
Fentanyl ( 
Midazolam-first protocol
Midazolam (1 mg/ml saline solution) is titrated in 1 ml/min increments until the patient is visibly relaxed but responsive (maximum midazolam 10 mg). Fentanyl (5 mcg/ml saline solution) is administered at a rate of 1 ml/min to a suitable endpoint of 25-50 mcg (see above).
The patient is continuously assessed, and SpO2 levels monitored. Once a suitable endpoint is achieved (patient relaxed but responsive), local anesthesia is administered and the procedure may commence.
The provision of safe sedation in the present study was to sustain throughout the sedation and recovery period the patient's ability to maintain consciousness/responsiveness and control of physiological parameters. This assessment is measured using the Ramsay Sedation Scale [16, 17] , with moderate sedation level defined as a score:
3-4; and by measurement of surrogates of over-sedation (SpO 2 ≤ 90% or the need for an airway opening maneuver). 
Data Extraction and Coding
Demographic information extracted included age, sex, smoking status, BMI, and ASA physical status classification [18] . All blood SpO 2 and EtCO 2 levels were extracted. Pre-and post-procedure systolic and diastolic blood pressure (SBP, DBP), respiration, and heart rate were collected and the differences calculated (i.e., change in vital signs). Administration times were recorded as the time between the first IV drug administration and the administration of local anesthesia (start of the clinical procedure). Recovery times were determined as the time from procedure end to patient discharge. Safe discharge was determined using criteria from a modified discharge scale described by Aldrete [19] . The total dosages of each drug administered were also recorded. Patient anxiety, procedure recollection, and satisfaction were captured through Likert scale questionnaire items (Appendix 2).
Data Analysis
Analysis was conducted using STATA Release 14 (StataCorp, College Station, TX, USA) [20] . Data were screened before analysis for statistical outliers. Cases with outliers and potential entry errors were reviewed to determine whether single data points or entire cases should be removed from the analysis. To remove potential bias associated with covariates in the secondary data, propensity scores were determined to control for the effects of demographic differences between the two groups [17] . Due to the small sample size, rather than using a matched pairs approach (which would cause further sample attrition) these propensity scores were used as a single summary covariate in linear and ordinal regression analyses, so that the outcomes described demonstrate only the relative effects of administration order. Statistical significance was set at P < 0.05.
RESULTS
Seventy-six of 80 charts were included in the final analysis, with 40 cases involving midazolam first and 36 involving fentanyl first. The charts removed from analysis were missing key demographic information that would allow for a propensity score to be calculated. Within the included charts there were also 9 single data points reflecting statistical outliers, data entry mistakes, or missing data for certain outcome measures; therefore, these cases were not included in the respective analyses requiring these variables. In addition, 6 charts did not include a satisfaction questionnaire, and 13 additional cases were missing the 24-to 48-hour satisfaction questionnaire responses. These charts were not included in the analyses related to satisfaction.
Demographics
Demographic information for the midazolam-first and fentanyl-first groups are summarized in Tables 1 and 2. Before propensity score analysis, the groups significantly Data presented as mean ±SD unless otherwise indicated. *Statistically significant at P < 0.05. ing for propensity scores, the two groups were statistically equivalent for potential covariates.
Patient Safety and Physiological Parameters
Changes in vital signs, and average SpO 2 and EtCO 2 levels according to administration group, are shown in Table 3 . After controlling for covariates, none of these physiological parameters significantly differed between the midazolam-first and fentanyl-first groups (P > 0.05).
For patient safety, verbal contact with the patients was maintained throughout the sedation period (Ramsay score -3), oxygenation desaturation (below 90%) was not observed, and no airway intervention was monitored.
Specific to the minimum SpO 2 levels experienced by the patients, there were no statistically significant differences;
however, there was a potential clinically significant difference, namely, the fentanyl-first group had five (14%) cases in which SpO 2 levels dropped below 92%, compared with zero in the midazolam-first group. SpO 2 levels never dropped below 90% in either group.
Administration and Recovery Times
There was no significant difference in average procedure length according to administration order (P > 0.05) ( 36.81 ± 9.12 β = 1.88; P = 0.44 Data presented as mean ±SD unless otherwise indicated. *Statistically significant at P < 0.05 Table 5 . Drug dosages recovery times (P > 0.05).
Drug Dosages
Controlling for covariates, there was a significant difference in the amount of midazolam administered (Table 5 ). When fentanyl was administered first, the total midazolam dosage was, on average, 2.43 mg less than when midazolam was administered first (β = -2.
43, t[70]
= -5.12; P < 0.001). The percent change indicated a 29% decrease in average midazolam dosages. There was no significant difference in total fentanyl dosage (P > 0.05).
Patient Satisfaction
Ordinal logistic regression revealed significant differences in response to the recollection item on the satisfaction questionnaires. On average, the odds of greater procedural recollection before discharge was 3. 
DISCUSSION
The purpose of this study was to elaborate on the effects of sedative/analgesic administration order when applied in a private practice dental office setting. This study revealed a 29% reduction in midazolam dosage when low-dose fentanyl opioid was administered first, further demonstrating a significant pharmacodynamic interaction that should be taken into consideration when prescribing drug order for moderate IV sedation in dentistry [6, 13] . Opioids are often described as having less profound effects on cardiovascular stability than sedative/hypnotic agents [11] . Therefore, use of a fentanyl-first protocol may be indicated to reduce overall midazolam dosage requirements, while still maintaining adequate patient sedation and operator satisfaction, and without increasing the amount of fentanyl required. Start anesthesia with local anesthetic administration 1. Wait for local anesthetic to take effect and then proceed with dental procedure. The sedationist/operator will be blinded to individual answers to this questionnaire.
Patient's level of anxiety or nervousness prior to the procedure.
